Ascendis ready for new hires after FDA approval

For a long time, Ascendis has been preparing for the approval of growth hormone Skytrofa, and the company can now execute launch and expansion plans.
Photo: Kevin Grønnemann/MedWatch
Photo: Kevin Grønnemann/MedWatch

Ascendis Pharma is chomping at the bit after securing a long-awaited approval for Transcon hGH, which will be marketed as Skytrofa. The company has already prepared launch plans to be initiated immediately.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading